MA45563A - Méthodes de traitement du cancer de l'ovaire - Google Patents

Méthodes de traitement du cancer de l'ovaire

Info

Publication number
MA45563A
MA45563A MA045563A MA45563A MA45563A MA 45563 A MA45563 A MA 45563A MA 045563 A MA045563 A MA 045563A MA 45563 A MA45563 A MA 45563A MA 45563 A MA45563 A MA 45563A
Authority
MA
Morocco
Prior art keywords
ovarian cancer
cancer treatment
treatment methods
methods
ovarian
Prior art date
Application number
MA045563A
Other languages
English (en)
Other versions
MA45563B1 (fr
Inventor
Mary Lynne Hedley
Robert Martell
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Priority claimed from PCT/US2017/040039 external-priority patent/WO2018005818A1/fr
Publication of MA45563A publication Critical patent/MA45563A/fr
Publication of MA45563B1 publication Critical patent/MA45563B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA45563A 2016-06-29 2017-06-29 Méthodes de traitement du cancer de l'ovaire MA45563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356461P 2016-06-29 2016-06-29
PCT/US2017/040039 WO2018005818A1 (fr) 2016-06-29 2017-06-29 Méthodes de traitement du cancer de l'ovaire

Publications (2)

Publication Number Publication Date
MA45563A true MA45563A (fr) 2019-05-08
MA45563B1 MA45563B1 (fr) 2024-05-31

Family

ID=91486473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45563A MA45563B1 (fr) 2016-06-29 2017-06-29 Méthodes de traitement du cancer de l'ovaire

Country Status (1)

Country Link
MA (1) MA45563B1 (fr)

Also Published As

Publication number Publication date
MA45563B1 (fr) 2024-05-31

Similar Documents

Publication Publication Date Title
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
IL263925A (en) Methods of treating ovarian cancer
DK3506854T3 (da) Brystbehandlingsindretning
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA47095A (fr) Traitement du palais mou
MA41449A (fr) Polythérapies pour le traitement de cancers
MA49295A (fr) Traitements du cancer de l'utérus
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA45429A (fr) Polythérapie pour le traitement du cancer
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA46361A (fr) Traitement du cancer de la prostate
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
DK3458052T3 (da) Kombinationsbehandling af cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
MA47408A (fr) Traitement du cancer